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Introduction: Hypertension is a significant risk factor for cardiovascular disease (CVD). The majority of patients,
however, cannot easily maintain a healthy blood pressure. Therefore, lifestyle modifications are important and may
include getting enough sleep. The purpose of this study was to determine the relationship between sleep duration
and hypertension, as defined by the Joint National Committee (JNC) 7 and JNC 8 guidelines.
Methods: We used the data from 6,365 individuals aged ≥ 18 years based on national data from a representative
sample of the 5th Korea National Health and Nutrition Examination Survey V-3 in 2012. The participants were
divided into three categories: JNC 7, JNC 8, and newly excluded only. The duration of sleep was classified as less
than 5, 6, 7, 8, or more than 9 hours.
Results: Compared with the appropriate sleep duration of 7 hours, with a sleep duration of less than 5 hours,
the recommended pharmacological treatment of hypertension rate increased 1.908-fold (95% CI = 1.483-2.456)
according to the JNC 8 guidelines and 1.864-fold (95% CI = 1.446-2.403) according to the JNC 7 guidelines.
However, there was no statistical difference with the other sleep categories.
Discussion: The recommended hypertension treatment rate increased significantly in the less than 5 hours sleep
group according to the JNC 8 guidelines. To manage hypertension effectively, it may be useful to maintain a
lifestyle of sleeping more than 6 hours.
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Hypertension is a well-known risk factor of the cardio-
vascular system [1] that increases the risk of cardiovas-
cular disease and places serious burdens on society and
the economy [2]. Koreans have a lower risk of cardiovas-
cular disease than that of Caucasians [3], but according
to the research of Park et al. [4], the cerebrovascular
disease risk for Koreans is high, and the research of* Correspondence: jeklee@pnu.edu
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creativecommons.org/publicdomain/zero/1.0/Kim et al. [5] shows a high prevalence of kidney disease
in the Korean population.
The most effective way to prevent hypertension-
related mortality or morbidity is preventing and treating
hypertension [6]. Although hypertension treatment
methods have improved over the last few decades, there
are still many patients that fail to reach their treatment
goals. The research of Kim et al. [7] shows that Koreans
are no exception. Treating hypertension is difficult and
complex; therefore, to reduce the risks of developing
hypertension-related disease, it is important to make
lifestyle changes such as adopting a low-salt diet, main-
taining appropriate weight, drinking in moderation, ex-
ercising regularly, not smoking, and dietary therapy [8,9].rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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cessary modifications.
In terms of lifestyle, recent epidemiological studies
suggest a minimum sleep duration to be obtained to
maintain health. Research argues that short sleep dur-
ation is related to the prevalence of hypertension [6,9].
Sleep deprivation significantly increases blood pressure
in both control and hypertension groups [10,11]. Simi-
larly, research suggests that an appropriate sleep dur-
ation can help to lower the prevalences of hypertension,
cardiovascular-related mortality, obesity, and metabolic
syndrome [12,13]. If sleep duration is too short or too
long, cardiovascular disease-related mortality increases
[14]. Obtaining the proper amount of sleep may help
prevent or treat hypertension. Kim et al. [15] argued that
the prevalence of insomnia in Korea is similar to that in
the western region of the continent (16 – 20%), and
sleep duration in Korea tends to be shorter than that in
other countries [16].
Past studies have analyzed hypertension patients in ac-
cordance with the former Joint National Committee
(JNC) 7 guidelines. Unlike JNC 7, the new treatment
guidelines (JNC 8) released in 2014 recommend that the
pharmacological treatment of hypertension maintains a
similar blood pressure in individuals over 60 years of
age, patients with diabetes, and patients with chronic
kidney disease [17]. This change in the guidelines decreases
the therapeutic target blood pressure range and may influ-
ence the correlation between the recommended hyperten-
sion treatment rate and sleep duration.
The aim of the current study is to understand which
populations need to consider sleep duration for the pre-
vention and treatment of hypertension, given the known
relationship between sleep duration and hypertension
and the JNC 8 hypertension treatment guidelines.
Methods
Research subjects
This research analyzed data collected from the third sur-
vey administered by the 5th Korea National Health and
Nutrition Examination Survey (KNHANES V-3) in 2012
[17]. KNHANES is an ongoing national study of the
health behaviors, health conditions, and food and nutri-
tional intake of the population. For the data sampling
frame of the KNHANES V (2010-2012), the 2009 popu-
lation and the market price survey of apartments in
2008 was analyzed. The subjects were selected based on
multistage, stratified sampling. The survey included a
health interview, nutrition survey, and physical examin-
ation. The health interviews and examination surveys
were conducted by mobile checkup centers, and the nu-
trition survey was conducted by visiting the subject’s
family in person. Of the 12,722 people who were the
subject of the KNHANES V-3 study, 8,057 individualsparticipated in the survey, which is a participation rate
of 80%. KNHANES analysis were approved by Korean
Centers for Disease Control and Prevention IRB and the
reference number was 2012-01EXP-01-2C.
Blood pressure measurement
Four nurses of the survey team of the Korea Centers for
Disease Control and Prevention were in charge of meas-
uring blood pressure. The nurses measured blood pres-
sure three times manually as part of the health screening
in the mobile checkup center. After the fourth survey, a
review of the quality controls for blood pressure mea-
surements found that the height of a subject’s arm might
cause errors. To compensate, the measured blood pres-
sure was adjusted accordingly. This work used the ad-
justed blood pressures for analysis.
Treatment group for hypertension
Group following the new treatment guidelines
Using the evidence-based guidelines for hypertension
treatment in adults suggested by JNC 8, [18] the
pharmacological treatment recommended group was de-
fined as follows:
1. Patients over 60 years of age with a systolic blood
pressure greater than or equal 150 mmHg or a
diastolic blood pressure greater than or equal
90 mmHg
2. Patients 60 years of age or younger with a systolic
blood pressure greater than or equal 140 mmHg or
a diastolic blood pressure greater than or equal
90 mmHg
3. Diabetes patients with a systolic blood pressure
greater than or equal 140 mmHg or a diastolic blood
pressure greater than or equal 90 mmHg
4. Chronic kidney disease patients with a systolic blood
pressure greater than or equal 140 mmHg or a
diastolic blood pressure greater than or equal
90 mmHg
5. Patients who already take hypertension medicine
Group defined by the existing guidelines
The treatment group that followed the JNC 7 [19] guide-
lines was identified as the JNC 7 group. The subjects
were defined as follows
1. Patients with a systolic blood pressure greater than
or equal to 140 mmHg or a diastolic blood pressure
greater than or equal to 90 mmHg.
2. Patients with diabetes or chronic kidney disease with
a systolic blood pressure greater than or equal to
130 mmHg or a diastolic blood pressure greater
than or equal to 80 mmHg
3. Patients who already takes hypertension medicine.
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The subject group classified as a treatment group by the
JNC 7 guidelines but excluded from the treatment group
when following the JNC 8 guidelines.
Sleep duration
The survey included in the KNHANES was used for
sleep duration data. The analysis used the answers to the
question, “How many hours do you sleep a day?” The
duration of sleep was categorized as less than 5 hours, 6,
7, 8, or more than 9 hours.
Statistical analysis
All data are presented as means ± SE or as prevalences
(%). Sampling weights were used to account for complex
sampling. For the fundamental characteristics of the
groups, basic features of the treatment groups, and
elemental characteristics according to sleep duration, we
conducted a Pearson’s chi-square test using complex
sampling in terms of the following criteria: gender,
prevalence of cardiovascular disease, diabetes, chronic
kidney disease, obesity, smoking, and moderate physical
activity. The continuous variables for age, systolic/dia-
stolic blood pressure, total cholesterol, triglycerides, fast-
ing plasma glucose, and sleep duration were analyzed by
linear regression analysis via complex sampling. For the
two treatment guidelines that have different standards
for classifying sleep duration, the odds ratio of theTable 1 Baseline characteristics of all study subjects and a co
groups
Variables Total subjects (n = 6,365) Treatment g
Male sex (%) 2,099 (49.2) 767 (53.2)
Mean age (yr) 44.9 ± 0.3 57.5 ± 0.5
Obesity (%) 1,663 (31.7) 773 (47.5)
Past history (%)
CVD† 269 (3.4) 181 (8.4)
DM 649 (9.7) 477 (26.1)
CKD 40 (0.6) 16 (1.2)
SBP (mmHg) 117.0 ± 0.3 134.4 ± 0.6
DBP (mmHg) 75.5 ± 0.2 83.5 ± 0.5
Total cholesterol (mg/dL) 188.2 ± 0.7 193.0 ± 1.2
Triglyceride (mg/dL) 131.3 ± 2.1 170.3 ± 4.9
FPG (mg/dL) 97.1 ± 0.4 107.8 ± 1.0
Current smoking (%) 743 (20.6) 227 (18.5)
Physical activity‡ (%) 791 (17.6) 235 (14.1)
Sleep duration (hours) 6.8 ± 0.29 6.7 ± 0.04
Values are presented as means ± SD or frequencies (%). P-value for treatment group
*Treatment group included participants taking antihypertensive medication.
†CVD included myocardial infarction, angina, and stroke.
‡Physical activity, moderate exercise at least three times a week.
CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood press
kidney disease.treatment groups was determined by logistic regression
analysis via complex sampling. Statistical analysis was
performed using SPSS 18.0 for Windows (SPSS, Chicago,
IL, USA), and a p value less than 0.05 was considered
statistically significant.Results
Baseline characteristics according to treatment group
There were 6,365 respondents of the KNHANES V-3
who were over 18 years of age, and their baseline char-
acteristics are presented in Table 1. The patients de-
fined by JNC 7 or JNC 8 treatment guidelines were
included in the treatment group, and the subjects ex-
cluded from both criteria were defined as the non-
treatment group. The adults who were already taking
blood pressure medication were included in the treat-
ment group.
Compared with the non-treatment group, the treat-
ment group showed a significantly higher ratio of men
and higher age. Systolic and diastolic blood pressures
as well as total cholesterol, triglycerides, fasting
plasma glucose, and diabetes prevalence were all
higher than those of the non-treatment group. The
prevalence of chronic kidney disease and obesity were
also higher. In the case of moderate exercise, the num-
ber of subjects was significantly fewer, and they had a
shorter sleep duration.mparison between the treatment and non-treatment
roup* (n = 1,754) Non-Treatment group (n = 4,723) P value
1,999 (47.6) 0.051





111.0 ± 0.3 <0.001
72.8 ± 0.2 <0.001
186.7 ± 0.9 <0.001
117.0 ± 2.0 <0.001
93.0 ± 0.3 <0.001
507 (21.2) 0.087
734 (21.7) 0.001
6.9 ± 0.03 <0.001
vs. non-treatment group.
ure; FPG, fasting plasma glucose; DM, diabetes mellitus; CKD, chronic
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the treatment group
There were 193 people defined by the JNC 7 guidelines,
but not by the new guidelines, as a treatment group;
these individuals were designated as newly excluded. A
comparison of this group with the new treatment guide-
lines group did not show significant differences in sys-
tolic blood pressure, but the JNC 8 guidelines group had
a higher diastolic blood pressure. Diabetes and fasting
plasma glucose levels were higher in the newly excluded
only group. The JNC 8 guidelines group had a signifi-
cantly greater prevalence of obesity (Table 2).The baseline and metabolic characteristics of all study
subjects classified by sleep duration
Table 3 shows the basic features of the population
groups categorized by sleep duration. The largest group
had 1,372 individuals with a sleep duration of 7 hours.
There were 793 individuals in the group with a sleep
duration of 5 hours or less. There were 362 individuals
in the group with a sleep duration of 9 hours or more.
The group with 5 hours or less sleep showed the highest
rate of cardiovascular disease and were of the highest
average age. The systolic and diastolic blood pressures
were also higher in this group than any other group, and
the fasting plasma glucose level was significantly higher.Table 2 Comparison between the JNC 8 and newly excluded
Variables Treatment category*
JNC 7 (n = 1,754) JNC 8 (n
Male sex (%) 767 (53.2) 54.1
Mean age (yr) 57.5 ± 0.5 57.9 ± 0.6
Obesity (%) 773 (47.5) 702 (48.8)
Past history (%)
CVD† 181 (8.4) 174 (8.9)
DM 477 (26.1) 382 (23.1)
CKD 16 (1.2) 21 (1.2)
SBP (mmHg) 134.4 ± 0.6 134.3 ± 0.
DBP (mmHg) 83.5 ± 0.5 83.9 ± 0.6
Total cholesterol (mg/dL) 192.9 ± 1.2 192.3 ± 1.
Triglyceride (mg/dL) 170.3 ± 4.9 166.6 ± 4.
FPG (mg/dL) 107.8 ± 1.0 105.6 ± 1.
Current smoking (%) 227 (18.5) 201 (18.3)
Physical activity‡ (%) 235 (4.1) 212 (14.5)
Sleep duration (hours) 6.7 ± 0.03 6.7 ± 0.04
Values are presented as means ± SD or frequencies (%). P-value for JNC 8 vs. newly
*Treatment category; JNC 7 included participants taking antihypertensive medicatio
antihypertensive medication and content with JNC 8 guidelines; Newly excluded on
†CVD included myocardial infarction, angina, and stroke.
‡Physical activity, moderate exercise at least three times a week.
CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood press
disease, JNC, Joint National Committee.The 7-hour sleep duration group had the highest ratio of
males.
The odds ratios for the rate of recommended
hypertension treatment according to the sleep duration
category
Compared with the group with 7 hours of sleep, the rec-
ommended treatment rate of hypertension was signifi-
cantly higher with a sleep duration of 5 hours or less
according to the JNC 7 guidelines (OR = 1.864, 95% CI =
1.446-2.403). However, the rest of the JNC 7 categories did
not show any significant difference in hypertension rates
(Table 4). This trend was also seen with the JNC 8 guide-
lines for a sleep duration of 5 hours or less (OR = 1.908,
95% CI = 1.483-2.456).
Discussion
Hypertension is one of the major causes of death. The
prevention and treatment of hypertension are key to de-
creasing overall mortality and morbidity rates [20,21].
However, the number of hypertensive patients who
maintain their blood pressure under the target is not
that high [6]. For this reason, lifestyle modifications
should be practiced. One new lifestyle modification is
obtaining enough sleep [5,9-11]. Other researchers have
reported that too short a sleep duration increases blood
pressure and the prevalence of hypertension. JNC 7only treatment groups
= 1,561) Newly excluded only (n = 193) P value
45.9 0.101





6 135.7 ± 1.1 0.268
80.3 ± 0.7 <0.001
4 198.0 ± 4.1 0.216
5 200.4 ± 28.6 0.249
0 125.2 ± 4.1 <0.001
26 (20.0) 0.737
23 (10.9) 0.249
6.8 ± 0.20 0.427
excluded only.
n and content with JNC 7 guidelines; JNC 8 included participants taking
ly included participants treated under JNC 7, but not JNC 8, guidelines.
ure; FPG, fasting plasma glucose; DM, diabetes mellitus; CKD, chronic kidney
Table 3 Baseline and metabolic characteristics of all study subjects classified by sleep duration
Variables Sleep duration (hours)
≤5 (n = 793) 6 (n = 1,284) 7 (n = 1,372) 8 (n = 1,164) ≥9 (n = 362) P value
Male sex (%) 240 (39.1) 535 (52.8) 567 (52.3) 470 (49.1) 137 (41.8) <0.001
Mean age (yr) 53.0 ± 0.9 44.5 ± 0.6 44.0 ± 0.5 42.9 ± 0.6 43.3 ± 1.3 <0.001
CVD* (%) 73 (6.2) 60 (3.2) 51 (2.5) 63 (3.4) 17 (3.0) 0.004
SBP (mmHg) 121.3 ± 0.9 117.8 ± 0.6 116.8 ± 0.6 116.5 ± 0.6 116.0 ± 1.0 <0.001
DBP (mmHg) 76.3 ± 0.6 76.3 ± 0.5 76.1 ± 0.4 75.3 ± 0.5 72.9 ± 0.9 0.005
Total cholesterol (mg/dL) 190.2 ± 1.7 187.9 ± 1.4 190.2 ± 1.4 186.1 ± 1.3 187.3 ± 3. 3 0.126
Triglyceride (mg/dL) 133.3 ± 5.1 129.5 ± 3.3 135.0 ± 4.4 129.4 ± 4.8 135.0 ± 7.0 0.748
FPG (mg/dL) 99.3 ± 0.9 96.3 ± 0.7 97.4 ± 0.8 96.3 ± 0.8 95.3 ± 1.2 0.018
Obesity (%) 277 (34.2) 428 (33.3) 422 (32.5) 333 (29.5) 104 (28.9) 0.303
Current smoking (%) 80 (16.1) 202 (22.8) 233 (23.1) 174 (19.1) 52 (20.7) 0.081
Physical activity† (%) 112 (16.2) 214 (17.5) 239 (20.4) 168 (15.1) 51 (17.3) 0.120
Values are presented as means ± SD or frequencies (%). P-value for sleep duration category.
*CVD included myocardial infarction, angina, and stroke.
†Physical activity, moderate exercise at least three times a week.
CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; DM, diabetes mellitus; CKD, chronic
kidney disease.
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JNC 8 was established in 2014 [17,19], the new treat-
ment guidelines of which are based on newly reported,
randomized control experiments, and these guidelines
permit a higher systolic blood pressure.
Past research on the relationship between sleep dur-
ation and hypertension was based on the JNC 7 guide-
lines. The question of whether the relationship between
hypertension and sleep duration is still maintained under
the JNC 8 guidelines prompted this research. In this
study, we examined the correlation between sleep dur-
ation and the recommended treatment rate of hyperten-
sion using the JNC 8 criteria. An earlier study reported a
hazard ratio of 1.20 (95% CI = 1.09-1.31) for short sleep
duration on hypertension prevalence, and this study sug-
gests 7 hours of sleep to be the appropriate duration
[22]. One meta-analysis reported that the odds ratio for
hypertension risk due to a shorter sleep duration is 1.20
(95% CI = 1.09-1.32). Based on other reports, too much
sleep can also increase hypertension risk (OR = 1.11,
95% CI = 1.05–1.17) [23]. Another study found that
short sleep duration increased the prevalence of hyper-
tension, but long sleep duration had no statistically sig-
nificant difference [24].Table 4 Odds ratios for the prevalence of hypertension accor
Prevalence* Sleep duration (hours)
≤5 6
JNC 7 1.864(1.446-2.403) 0.973(0.785-1.206)
JNC 8 1.908(1.483-2.456) 1.009(0.811-1.255)
*Prevalence, prevalence of hypertension; JNC 7 included prevalence of hypertensio
medication; JNC 8 included prevalence of hypertension according to JNC 8 guidelin
JNC, Joint National Committee.In the current study, we defined the standard duration
of sleep as 7 hours in accordance with recent research
[25,26] A sleep duration of less than 5 hours increases
the need for hypertension treatment by 1.864-fold (95%
CI = 1.446-2.403) according to the JNC 7 guidelines, and
by 1.908-fold (95% CI = 1.483-2.456) according to the
JNC 8 guidelines. Both guidelines by JNC 7 and JNC 8
showed that short sleep duration increases the rate of
recommend treatment of hypertension alike, which
are very similar to the former results [22,23]. JNC 8
tends to exclude obesity or diabetes cases in their
estimates, which were considered under the JNC 7
guidelines. Because of these excluded groups, the
prevalence of cardiovascular disease and diastolic
blood pressure was higher with the former guidelines.
Despite the differences among the subjects, a sleep
duration of less than 5 hours increased the hyperten-
sion risk by similar levels. However, a long sleep
duration did not correlate with the prevalence of
hypertension. Compared with other countries, this dif-
ference may be related to the shorter sleep duration of
Korean individuals. Together, these results support the
recommendation for a sleep duration of 6 hours or
more among Korean hypertension patients.ding to sleep duration category
7 8 ≥9
1.00 (reference) 0.947(0.752-1.193) 0.954(0.692-1.315)
1.00 (reference) 0.971(0.776-1.215) 0.988(0.708-1.379)
n according to JNC 7 guidelines and the subjects taking antihypertensive
es and the subjects taking antihypertensive medication.
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plains the mechanism linking short sleep duration to
hypertension prevalence. As sleep duration shortens, the
waking state is maintained and the sympathetic nervous
system stimulated. This also increases nighttime blood
pressure levels. An increased heart rate and elevated salt
intake also present a risk of hypertension [6,27].
This study’s findings may be generalized to a larger
population, because it analyzed representative data
among a diverse and large group of Koreans. It also de-
termined the appropriate amount of sleep in accordance
with the treatment guidelines suggested in 2014. How-
ever, there are some limitations to how well the study
findings can be applied to the general population. First,
this research is based on a cross-sectional survey; thus,
while it may suggest a correlation between hypertension
and sleep duration, it cannot identify the causal link with
any certainty. Second, the survey on sleep duration was
based on one question. In addition, there was a report
suggesting that the quality of sleep influences the hyper-
tension prevalence more than does the quantity of sleep
[6,28,29], and this was not addressed in the current
study. Third, even though the importance of this associ-
ation was weakened by the JNC 8 guidelines, 24-hour
blood monitoring data are still significant for assessing
blood pressure status. However, the KNHANES V3 data
did not include 24-hour blood monitoring data, which
limits our study. Finally, the proportions of males and
older patients were higher among participants with short
sleep duration. Gender and age were two of the most
significant factors influencing hypertension; the impact
of sleep duration may be minor for the treatment and
management of hypertension. However, gender and age
are not modifiable, and although the lifestyle modifica-
tion of increased sleep may have only a weak effect, it
still warrants recommendation due to even this small
influence.Conclusions
In conclusion, there was a statistically significant in-
crease in the rate of recommended hypertension treat-
ment among individuals with a short sleep duration,
regardless of whether the hypertension treatment
guidelines were according to JNC 7 or JNC 8. To con-
trol hypertension, it is useful to modify lifestyle to
maintain a proper sleep duration of more than 6 hours.
This study is limited by data collected via a cross-
sectional survey that did not investigate sleep suffi-
ciently. A prospective study is needed to overcome
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